In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other most ...

A month has gone by since the last earnings report for Apellis Pharmaceuticals, Inc. (APLS). Shares have added about 18.4% in that time frame, outperforming the S&P 500. Will the recent positive ...

It has been about a month since the last earnings report for Apellis Pharmaceuticals, Inc. (APLS). Shares have lost about 1.9% in that time frame, underperforming the S&P 500. Will the recent ...

Apellis Pharmaceuticals, Inc. (APLS) reported $166.8 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.2%. EPS of -$0.74 for the same period compares ...